Annals of Hematology

, Volume 98, Issue 11, pp 2613–2615 | Cite as

Epstein–Barr virus–associated post-transplant lymphoproliferative disorder among long-term survivors of adults after single cord blood transplantation without antithymocyte globulin

  • Masamichi Isobe
  • Takaaki KonumaEmail author
  • Seiko Kato
  • Maki Oiwa-Monna
  • Yuta Kaito
  • Satoshi Takahashi
  • Arinobu Tojo
Letter to the Editor

Dear Editor,

Epstein–Barr virus (EBV)–associated post-transplant lymphoproliferative disorder (PTLD) is one of the significant cause of morbidity and mortality among patients after allogeneic hematopoietic cell transplantation (HCT). More than 80% of case usually developed EBV-PTLD within the first year following HCT prior to reconstitution of EBV-reactive adaptive immune response [1, 2]. Cord blood transplantation (CBT) and use of antithymocyte globulin (ATG) was well-known risk factor for development of EBV-PTLD [2, 3]. However, little is known about the long-term incidence of EBV-PTLD after CBT without ATG. Therefore, we retrospectively examined the incidence and outcomes for adults developed EBV-PTLD after CBT without ATG.

Between August 1998 and July 2018, 278 consecutive adult patients who received single-unit CBT as the first allogeneic HCT at our institution were included in this retrospective study. The median age at CBT was 44 years (range, 16 to 69 years). The most common...



The authors thank all of the physicians and staff at the hospital and the cord blood banks in Japan for their help in this study.

Authors’ contributions

M.I. collected data, and wrote the paper. T.K. conceived the project, designed the research, collected data, analyzed data and wrote the paper. S.K. and M.O. collected data. All the other authors participated in the treatment of the patients, acquired the clinical data, and contributed to writing the paper. All authors approved the final version.

Compliance with ethical standards

Written informed consent was acquired from all patients and healthy subjects. The Institutional Review Board of the Institute of Medical Science, University of Tokyo approved this study (30-111-B20190423).

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Dierickx D, Habermann TM (2018) Post-transplantation lymphoproliferative disorders in adults. N Engl J Med 378:549–562CrossRefGoogle Scholar
  2. 2.
    Al Hamed R, Bazarbachi AH, Mohty M (2019) Epstein-Barr virus-related post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of allogeneic stem cell transplantation: a comprehensive review from pathogenesis to forthcoming treatment modalities. Bone Marrow Transplant. In pressGoogle Scholar
  3. 3.
    Fujimoto A, Hiramoto N, Yamasaki S, Inamoto Y, Uchida N, Maeda T, Mori T, Kanda Y, Kondo T, Shiratori S, Miyakoshi S, Ishiyama K, Ikegame K, Matsuhashi Y, Tanaka J, Ichinohe T, Atsuta Y, Ogata M, Suzuki R (2019) Risk factors and predictive scoring system for post-transplant lymphoproliferative disorder after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 25:1441–1449CrossRefGoogle Scholar
  4. 4.
    Barker JN, Martin PL, Coad JE, DeFor T, Trigg ME, Kurtzberg J, Weisdorf DJ, Wagner J (2001) Low incidence of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorders in 272 unrelated-donor umbilical cord blood transplant recipients. Biol Blood Marrow Transplant 7:395–399CrossRefGoogle Scholar
  5. 5.
    Brunstein CG, Weisdorf DJ, DeFor T, Barker JN, Tolar J, van Burik JA, Wagner JE (2006) Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 108:2874–2880CrossRefGoogle Scholar
  6. 6.
    Dumas PY, Ruggeri A, Robin M, Crotta A, Abraham J, Forcade E, Bay JO, Michallet M, Bertrand Y, Socié G, Ionescu I, Gluckman E, Milpied N, Rocha V (2013) Incidence and risk factors of EBV reactivation after unrelated cord blood transplantation: a Eurocord and Société Française de Greffe de Moelle-Therapie Cellulaire collaborative study. Bone Marrow Transplant 48:253–256CrossRefGoogle Scholar
  7. 7.
    Sanz J, Arango M, Senent L, Jarque I, Montesinos P, Sempere A, Lorenzo I, Martín G, Moscardó F, Mayordomo E, Salavert M, Cañigral C, Boluda B, Salazar C, López-Hontangas JL, Sanz MA, Sanz GF (2014) EBV-associated post-transplant lymphoproliferative disorder after umbilical cord blood transplantation in adults with hematological diseases. Bone Marrow Transplant 49:397–402CrossRefGoogle Scholar
  8. 8.
    Naik S, Riches M, Hari P, Kim S, Chen M, Bachier C, Shaughnessy P, Hill J, Ljungman P, Battiwalla M, Chhabra S, Daly A, Storek J, Ustun C, Diaz MA, Cerny J, Beitinjaneh A, Yared J, Brown V, Page K, Dahi PB, Ganguly S, Seo S, Chao N, Freytes CO, Saad A, Savani BN, Woo Ahn K, Boeckh M, Heslop HE, Lazarus HM, Auletta JJ, Kamble RT (2019) Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study. Transpl Infect Dis 21:e13145Google Scholar
  9. 9.
    Servais S, Hannon M, Peffault de Latour R, Socie G, Beguin Y (2017) Reconstitution of adaptive immunity after umbilical cord blood transplantation: impact on infectious complications. Stem Cell Investig 4:40CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Hematology/Oncology, The Institute of Medical ScienceThe University of TokyoTokyoJapan

Personalised recommendations